利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.039 秒)

    KIR-binding agents and methods of use thereof
    6.
    发明授权
    KIR-binding agents and methods of use thereof 有权
    KIR结合剂及其使用方法

    公开(公告)号：US08388970B2

    公开(公告)日：2013-03-05

    申请号：US12244101

    申请日：2008-10-02

    申请人： Søren Berg Padkær ,  Peter Andreas Nicolai Reumert Wagtmann ,  Pieter Spee ,  Stefan Zahn ,  Kristian Kjærgaard ,  Anders Svensson

    发明人： Søren Berg Padkær ,  Peter Andreas Nicolai Reumert Wagtmann ,  Pieter Spee ,  Stefan Zahn ,  Kristian Kjærgaard ,  Anders Svensson

    IPC分类号： A61K39/395 ,  A61K39/00

    CPC分类号： C07K16/2803 ,  C07K16/28 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76

    摘要： The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

    摘要翻译： 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来减少或阻断HLA结合。

    KIR-binding agents and methods of use thereof
    7.
    发明授权
    KIR-binding agents and methods of use thereof 有权
    KIR结合剂及其使用方法

    公开(公告)号：US08222376B2

    公开(公告)日：2012-07-17

    申请号：US11813402

    申请日：2006-01-06

    申请人： Søren Berg Padkær ,  Peter Reumert Wagtmann ,  Pieter Spee ,  Stefan Zahn ,  Kristian Kjærgaard

    发明人： Søren Berg Padkær ,  Peter Reumert Wagtmann ,  Pieter Spee ,  Stefan Zahn ,  Kristian Kjærgaard

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395

    CPC分类号： C07K16/2803 ,  C07K16/28 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76

    摘要： The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

    摘要翻译： 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了用于减少KIR介导的NK细胞细胞毒性抑制的单克隆抗体的方法和试剂，而不通过例如还原或阻断KIR二聚化来降低或阻断HLA结合。

    Methods of Identifying Antibodies to Ligands of Orphan Receptors
    8.
    发明申请
    Methods of Identifying Antibodies to Ligands of Orphan Receptors 审中-公开
    识别孤儿受体配体的抗体的方法

    公开(公告)号：US20090010843A1

    公开(公告)日：2009-01-08

    申请号：US12067686

    申请日：2006-09-25

    申请人： Pieter Spee ,  Peter Andreas Wagtmann ,  Thomas Chin Che Tan

    发明人： Pieter Spee ,  Peter Andreas Wagtmann ,  Thomas Chin Che Tan

    IPC分类号： A61K51/10 ,  G01N33/53 ,  C12P21/04 ,  G01N33/00 ,  C07K16/00 ,  C12N5/02 ,  A61K39/395

    CPC分类号： G01N33/5032 ,  G01N33/505 ,  G01N2333/70535 ,  G01N2333/70596

    摘要： Described is a method of identifying antibodies against hitherto unknown ligands of orphan receptors or other orphan ligands, i.e., receptors or other ligands where the counter-ligand has not yet been identified. The availability of antibodies binding to the unknown ligand significantly facilitates their isolation and characterization, and the identified antibodies can themselves be useful for treating patients with cancer or autoimmune diseases, or other disorders. An exemplary embodiment provides for a method designated Identification of Therapeutic Antibodies by Competitive Screening (ITACS). Described are also fusion proteins comprising a soluble portion of an orphan receptor, such as NKp30, and the Fc portion of an antibody. The fusion proteins typically comprise a Flexible Transmembrane Linker (FTL), i.e., a linker comprising a portion of a transmembrane domain of the orphan receptor.

    摘要翻译： 描述了鉴定针对孤儿受体或其他孤儿配体的迄今未知配体的抗体的方法，即受体或其他配体，其中反配体尚未被鉴定。 结合未知配体的抗体的可用性显着促进其分离和表征，并且鉴定的抗体本身可用于治疗患有癌症或自身免疫性疾病或其他疾病的患者。 一个示例性实施方案提供了通过竞争筛选（ITACS）命名为治疗性抗体鉴定的方法。 还描述了包含孤立受体的可溶性部分如NKp30的融合蛋白和抗体的Fc部分。 融合蛋白通常包含柔性跨膜连接子（FTL），即包含孤儿受体的一部分跨膜结构域的接头。